Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients.
Reijm EA, Sieuwerts AM, Smid M, Vries JB, Mostert B, Onstenk W, Peeters D, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, van Galen A, Kraan J, Jansen MP, Gratama JW, Foekens JA, Martens JW, Berns EM, Sleijfer S. Reijm EA, et al. Among authors: hamberg p. BMC Cancer. 2016 Feb 18;16:123. doi: 10.1186/s12885-016-2155-y. BMC Cancer. 2016. PMID: 26892682 Free PMC article.
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
Hamberg P, Steeghs N, Loos WJ, van de Biessen D, den Hollander M, Tascilar M, Verweij J, Gelderblom H, Sleijfer S. Hamberg P, et al. Br J Cancer. 2010 Jun 8;102(12):1699-706. doi: 10.1038/sj.bjc.6605696. Epub 2010 May 18. Br J Cancer. 2010. PMID: 20485286 Free PMC article. Clinical Trial.
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
Hamberg P, Bos MM, Braun HJ, Stouthard JM, van Deijk GA, Erdkamp FL, van der Stelt-Frissen IN, Bontenbal M, Creemers GJ, Portielje JE, Pruijt JF, Loosveld OJ, Smit WM, Muller EW, Schmitz PI, Seynaeve C, Klijn JG; Dutch Breast Cancer Trialists' Group (BOOG). Hamberg P, et al. Clin Breast Cancer. 2011 Apr;11(2):103-13. doi: 10.1016/j.clbc.2011.03.003. Epub 2011 Apr 11. Clin Breast Cancer. 2011. PMID: 21569996 Clinical Trial.
Effects of CYP induction by rifampicin on tamoxifen exposure.
Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, de Jonge E, Jager A, Seynaeve C, van Schaik RH, Verweij J, Mathijssen RH. Binkhorst L, et al. Among authors: hamberg p. Clin Pharmacol Ther. 2012 Jul;92(1):62-7. doi: 10.1038/clpt.2011.372. Epub 2012 May 23. Clin Pharmacol Ther. 2012. PMID: 22617226 Clinical Trial.
Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients.
Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, van Galen A, Peeters DJ, Dirix LY, Seynaeve CM, Jager A, de Jongh FE, Hamberg P, Stouthard JM, Kehrer DF, Look MP, Smid M, Gratama JW, Foekens JA, Martens JW, Sleijfer S. Mostert B, et al. Among authors: hamberg p. Ann Oncol. 2015 Mar;26(3):510-6. doi: 10.1093/annonc/mdu557. Epub 2014 Dec 3. Ann Oncol. 2015. PMID: 25471333 Free article. Clinical Trial.
148 results